Epilepsy

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 28, 2026.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 21, 2026.

Oak Hill Bio announced dosing of the first participant in BEACON, a pivotal phase 3 trial evaluating rugonersen, an antisense oligonucleotide originally developed by Roche, for Angelman syndrome.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 14, 2026.

Uma Menon, MD, Adult Neurology Residency Program Director at Allina Health Brain and Spine Institute, shares lessons on navigating fellowship, finding the right career path, building expertise, and maintaining balance throughout a career in neurology.

In a recently published phase 3 post hoc analysis, treatment with fenfluramine was associated with early, sustained reductions in fall-related seizures among patients with Lennox-Gastaut syndrome.

Cynthia Keator, MD, director of neurology at Cook Children's Hospital, shares her perspective on building longitudinal Lennox-Gastaut syndrome care plans, navigating the pediatric-to-adult transition, and what the field needs to do better for patients and families.

Epilepsy expert Susan Duberstein, MD, explores how multidisciplinary neurocutaneous clinics improve diagnosis, surveillance, care coordination, and long-term outcomes for patients with complex neurocutaneous syndromes.

Ahead of World Brain Day, NeurologyLive explores 5 emerging strategies for preventing neurologic disease, from modifiable dementia risk factors to GLP-1 drugs, sleep science, the gut brain axis, and wearable technology.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 10, 2026.

Led by Na Tosha Gatson, MD, PhD, FAAN, director of the Center for Neuro-Oncology at the Indiana University Health Neurosciences and Cancer Institutes, this new column translates complex neuro-oncology topics into accessible, evidence-based insights.

Cleveland Clinic pilots HAP-E, guiding older adults to manage epilepsy and cognitive decline with lifestyle tools, medication support, and virtual access.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 3, 2026.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 26, 2026.

A pair of neurologists discussed a new analysis suggesting that gender-affirming hormone therapy was not associated with an increased risk of seizure-related hospitalization among transgender women.

Three of 6 patients in the first low-dose cohort achieved seizure reductions of 79% to 100% at months 4 through 6, with no serious adverse events reported to date.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 19, 2026.

Irfan Qureshi, MD, chief medical officer at Biohaven, discusses newly reported data on opakalim, highlighting durable seizure control, favorable CNS tolerability, and the investigational agent’s potential role across multiple epilepsy syndromes.

Updated clinical data highlight opakalim’s ongoing development in epilepsy, with pivotal focal epilepsy results expected later this year.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 29, 2026.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 22, 2026.

Anup Patel, MD, pediatric epileptologist at Nationwide Children’s Hospital and leader within the Pediatric Epilepsy Research Consortium, discusses evolving AI-driven initiatives, Lennox-Gastaut syndrome research priorities, and future directions in pediatric epilepsy care.

Armin Jewell, MD, neurologist and epilepsy specialist at Allina Health Brain and Spine Institute, discusses the clinical implementation of the Zeto One point-of-care EEG headset and its potential role in improving seizure assessment and neurologic care access in community settings.

A prospective postapproval study showed that responsive neurostimulation with the RNS System was associated with sustained seizure reductions and a favorable interim safety profile over 3 years in adults with drug-resistant focal epilepsy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 8, 2026.